Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

Net Debt Summary of Devyser Diagnostics AB (publ)

Devyser Diagnostics AB (publ)'s latest annual net debt in 2023 was -188.09 Million SEK , up 45.06% from previous year.
Devyser Diagnostics AB (publ)'s latest quarterly net debt in 2024 Q2 was -136.2 Million SEK , up 7.16% from previous quarter.
Devyser Diagnostics AB (publ) reported annual net debt of -342.39 Million SEK in 2022, up 6.11% from previous year.
Devyser Diagnostics AB (publ) reported annual net debt of -364.67 Million SEK in 2021, down -2871.72% from previous year.
Devyser Diagnostics AB (publ) reported quarterly net debt of -136.2 Million SEK for 2024 Q2, up 7.16% from previous quarter.
Devyser Diagnostics AB (publ) reported quarterly net debt of -146.7 Million SEK for 2024 Q1, up 22.01% from previous quarter.

Annual Net Debt Chart of Devyser Diagnostics AB (publ) (2023 - 2018)

Historical Annual Net Debt of Devyser Diagnostics AB (publ) (2023 - 2018)

Year	Net Debt	Net Debt Growth
2023	-188.09 Million SEK	45.06%
2022	-342.39 Million SEK	6.11%
2021	-364.67 Million SEK	-2871.72%
2020	13.15 Million SEK	-2.47%
2019	13.49 Million SEK	517.96%
2018	2.18 Million SEK	0.0%

Year	Net Debt	Net Debt Growth
2024 Q3	-157.7 Million SEK	19.09%
2024 Q2	-136.2 Million SEK	7.16%
2024 Q1	-146.7 Million SEK	22.01%
2023 FY	-188.09 Million SEK	45.06%
2023 Q4	-188.09 Million SEK	12.02%
2023 Q3	-213.8 Million SEK	6.92%
2023 Q2	-229.7 Million SEK	27.61%
2023 Q1	-317.3 Million SEK	7.33%
2022 Q1	-399.8 Million SEK	-9.63%
2022 Q3	-364.6 Million SEK	4.7%
2022 Q2	-382.6 Million SEK	4.3%
2022 Q4	-342.39 Million SEK	6.09%
2021 Q4	-364.67 Million SEK	0.0%

Peer Net Debt Comparison of Devyser Diagnostics AB (publ)

Name	Net Debt	Net Debt Difference
AroCell AB (publ)	-50.72 Million SEK	-270.838%
Immunovia AB (publ)	-72.5 Million SEK	-159.441%
Prostatype Genomics AB (publ)	-2.61 Million SEK	-7093.117%
SenzaGen AB	-15.95 Million SEK	-1079.236%
Spermosens AB	5.02 Million SEK	3843.284%